Company enlists Havas Health & You,
Trinity Life Sciences to help build CyPath® Lung brand
bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW) today
announced its commercialization team, including the addition of
Julie Anne Overton, a veteran of print and broadcast journalism,
corporate communications and federal public affairs, as bioAffinity
Technologies’ Director of Communications, and the marketing and
advertising firms of Havas Health & You and Trinity Life
Sciences to help build the CyPath® Lung brand and position it for
success in the cancer diagnostics sector.
CyPath® Lung is a non-invasive test that detects early-stage
lung cancer by automated flow cytometry and machine learning.
“CyPath® Lung has the potential to change the paradigm for the
detection of early-stage lung cancer, and we have selected a team
that can build our brand with intention and establish a genuine
connection with physicians and patients who put their trust in us,”
bioAffinity Technologies President and CEO Maria Zannes said. “To
that end, in addition to hiring Julie Anne, we have engaged firms
with excellent credentials in the healthcare and biotech industries
who will bring creativity, purpose and strategic thinking to our
story.”
Havas Health & You, the world’s largest global health
network, is focused on promoting healthy living decisions across
the entire health ecosystem. The firm is creating the branding and
broader marketing strategy to align with the need for a
patient-friendly diagnostic that gives physicians another tool to
assess the potential or presence of lung cancer in their high-risk
patients.
“Working with partners that create innovative solutions for
physicians and the patients they serve aligns directly with our
network’s focus on human purpose,” said Jeff Hoffman, Chief
Development Officer and Partner at Havas Health & You. “We’re
so excited to work with bioAffinity during this next step of their
journey as a company, and I can’t think of a more meaningful way to
start our partnership with Trinity Life Sciences than through our
work on this project together.”
Trinity Life Sciences, a trusted strategic commercialization
partner providing evidence-based solutions for the life sciences,
is providing advisory services, insights and analytics to
bioAffinity Technologies’ marketing strategy for CyPath® Lung.
“We are delighted to partner with bioAffinity on their
commercialization of CyPath®, an accurate, non-invasive and
cost-effective method of detecting lung cancer early,” said Rich
Caligaris, Managing Director, Trinity Life Sciences. “Trinity’s
extensive commercialization experience will support bioAffinity’s
efforts to get this novel flow cytometry test to patients in need
as effectively and quickly as possible. With our over 25-year
history of offering evidence-based solutions and commitment to a
greater purpose, we are honored to help see CyPath® through to its
next phase of growth.”
Overton is a senior communications executive with expertise in
communication principles, strategic planning and achieving
organizational goals in a competitive environment. “I am honored to
join bioAffinity Technologies at an exciting time in the Company’s
history, and I look forward to partnering with Havas and Trinity to
introduce physicians, patients and investors to the proprietary
technology behind our CyPath® Lung test for the detection of
early-stage lung cancer,” Ms. Overton said.
Prior to joining bioAffinity Technologies, Ms. Overton managed a
comprehensive public affairs program for the USDA Forest Service.
She began her career as a print and broadcast journalist, including
more than a decade as a producer at the Washington, DC, bureau of
CBS News. Prior to covering the Congress for CBS News, she served
as Press Secretary for the late Congressman Charles Wilson (D-TX).
She later joined Security Capital Group, a $24 billion global real
estate operating company that was subsequently acquired by GE
Capital, and served as Director of Communications and Investor
Relations for a family of venture capital funds.
bioAffinity Technologies is implementing a regional rollout of
CyPath® Lung, a noninvasive test for the early detection of lung
cancer, in partnership with Precision Pathology Services, a
commercial clinical laboratory. In a recent clinical trial, CyPath®
Lung showed 92% sensitivity and 87% specificity in high-risk
patients who had nodules smaller than 20 millimeters or no nodules
in the lung, with an area under the ROC curve of 94%. CyPath® Lung
uses automated flow cytometry developed with machine learning to
analyze patient samples to reliably predict the presence of lung
cancer.
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW) addresses
the need for noninvasive diagnosis of early-stage cancer and
diseases of the lung, and targeted cancer treatment. The Company’s
first product, CyPath® Lung, is a non-invasive test that has shown
high sensitivity and specificity for the detection of early-stage
lung cancer. CyPath® Lung is marketed as a Laboratory Developed
Test (LDT) by Precision Pathology Services. OncoSelect
Therapeutics, LLC, a subsidiary of bioAffinity Technologies, is
advancing its discoveries shown in vitro to kill cancer cells
without harm to normal cells. Research and optimization of the
Company’s platform technologies are conducted in its laboratories
at The University of Texas at San Antonio.
About Havas Health & You
Havas Health & You unites Havas Life, Health4Brands (H4B),
Lynx, Red Havas and Havas Health Plus, all wholly owned health and
communications networks, with the consumer health businesses and
practices of Havas Creative Group. The network's approach is
centered around Human Purpose and has the talent, tenacity, and
technology that health companies, brands and people need to thrive
in today's world. For more information, go to
www.HavasHealthandYou.com.
About Trinity Life Sciences
Trinity Life Sciences is a trusted strategic commercialization
partner, providing evidence-based solutions for the life sciences.
With 25 years of experience, Trinity is committed to
revolutionizing the commercial model by providing exceptional
levels of service, powerful tools and data-driven insights.
Trinity’s range of products and solutions includes industry-leading
benchmarking solutions, powered by TGaS Advisors. To learn more
about how Trinity is elevating life sciences and driving evidence
to action, visit trinitylifesciences.com.
Forward-Looking Statements
This press release contains forward-looking statements,
including statements regarding the anticipated use of proceeds from
the Company’s offering of common shares. Forward-looking statements
can be identified by words such as “believes,” “expects,”
“estimates,” “intends,” “may,” “plans,” “will” and similar
expressions, or the negative of these words. Such forward-looking
statements are based on facts and conditions as they exist at the
time such statements are made and predictions as to future facts
and conditions. Readers of this press release are cautioned not to
place undue reliance on any forward-looking statements. The Company
does not undertake any obligation to update any forward-looking
statement relating to matters discussed in this press release,
except as may be required by applicable securities laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230213005204/en/
Company Contact: Julie Anne Overton, Director of
Communications jao@bioaffinitytech.com 505-577-0918
bioAffinity Technologies (NASDAQ:BIAF)
Historical Stock Chart
From Jun 2024 to Jul 2024
bioAffinity Technologies (NASDAQ:BIAF)
Historical Stock Chart
From Jul 2023 to Jul 2024